Warp Sciences Raises $215M Series A Led by Lightspeed Venture Partners

Warp Sciences, a San Francisco biotechnology infrastructure company, launched on 22 October 2026 with a $215 million Series A led by Lightspeed Venture Partners. MedPath Trial and Pulse 2.0 carried the launch that day. Venture Capital Tracker reports a $865 million post-money valuation, which Bloomberg attributes to the company.

The announcement contains two numbers that matter to readers. The first is the $215 million round, which the outlets reviewed report consistently. The second is the $865 million post-money valuation, which appears in two outlets and traces back to a citation of the company rather than to a regulatory filing. This article keeps those two numbers separate throughout, and it marks where the coverage is silent.

How much did Warp Sciences raise and who invested?

Warp Sciences raised $215 million in a round that coverage labels a Series A. Lightspeed Venture Partners led it, according to MedPath Trial. The same report lists 18 other investors, including Premji Invest, Mayfield, IVP, Lux, Menlo Ventures and SignalFire.

Pulse 2.0 gives a shorter group of participants. It names Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures and several other venture capital firms, and it describes the financing as led by Lightspeed. The amount and the lead match across the reports, so the investor list is the main place where the outlets differ in detail.

Several outlets date the announcement to 22 October 2026. MedPath Trial, Pulse 2.0 and Emergent carry the launch that day, and all three report the same $215 million. The table below lists each reported item with the outlets that carry it, so a reader can check every line against its source.

What does Warp Sciences do?

Warp Sciences is a contract research organization for chemistry. Pulse 2.0 describes it as integrating artificial intelligence, robotics and medicinal chemistry expertise. The company aims to build a U.S.-based chemistry CRO that shortens the path from molecular design to a tested compound.

Its initial service is lead optimization analog synthesis, in which scientists make and compare variations of a molecule while searching for a drug candidate. The company says it will not run its own drug pipeline. Customers keep control of their programs, and Warp provides the chemistry work.

The company's stated aim is to shorten the path from molecular design to a tested compound. The coverage also says the approach seeks to bring back labor-intensive chemistry work that is often outsourced to Chinese contractors. That shift is presented as a response to intellectual property and supply-chain risks. The model is therefore a service business: the chemistry is done for others, and the outcome belongs to the customer.

Who founded Warp Sciences?

MedPath Trial and Pulse 2.0 name Kevin Weil as co-founder and CEO. Emergent reports that Weil led OpenAI's AI-for-science division until earlier in 2026. The coverage reviewed does not name any other founders.

Kevin Weil is the central figure in the launch. Emergent's headline names him, and MedPath Trial and Pulse 2.0 list him as co-founder and CEO. Emergent says he led OpenAI's AI-for-science division until earlier in 2026. Neither the founder title nor the OpenAI role is confirmed by a filing in the coverage reviewed.

How much has Warp Sciences raised in total?

The coverage reports one round, the $215 million Series A. No earlier round or cumulative total is reported, so $215 million is the round size, not a total raised to date.

Readers comparing this with other funding announcements should keep the two measures apart. A round size describes one financing event. A total raised describes every round a company has closed. The coverage gives only the first. The valuation is a third measure, and it describes the price implied by the financing rather than the company's revenue. Venture Capital Tracker makes that point directly, noting that the $865M post-money valuation is a financing valuation, not revenue or evidence that the labs have reached scale.

How does Warp Sciences position itself against overseas chemistry providers?

Warp Sciences positions itself as a U.S.-based alternative to overseas chemistry providers. The pitch centers on bringing labor-intensive chemistry work back from China, where it is often outsourced, and on stronger intellectual property protection. Coverage does not include pricing or performance data to test that pitch.

The pitch rests on two claims. The first is cost and location: the company wants to offer competitive pricing against overseas providers. The second is protection: it emphasizes stronger intellectual property safeguards than those providers offer. Coverage links both claims to rising U.S.-China tensions in drug supply chains, which give customers a reason to look for domestic capacity. These are claims about what the company intends to offer. The coverage does not test them against prices, throughput or results.

Every row marked "Not in the coverage" is a question a buyer would ask first. None of them is answered in the sources reviewed, so the table is the clearest statement of what this article cannot tell you.

What will the $215 million be used for?

The coverage describes only the plan the company has stated. Warp intends to build increasingly automated chemistry labs that generate experimental data, which then improves its AI models, according to AIPressRoom. The company's logic is that better models help customers evaluate more potential drug candidates.

Venture Capital Tracker's reading of Lightspeed's investment memo adds a reason the company gives for the approach. It argues that faster molecular design runs into a laboratory bottleneck, and that Warp aims to address it by capturing and using process data from its labs. The coverage does not break the $215 million down by use, so the plan is a direction rather than a budget.

What's still unclear?

• Valuation source. The $865 million figure appears in Emergent and Venture Capital Tracker, and Venture Capital Tracker attributes it to Bloomberg citing the company. No regulatory filing is cited, so the figure is unverified by a filing.
• Series A label. Emergent and Venture Capital Tracker use the Series A label. MedPath Trial and Pulse 2.0 describe the $215 million only as funding, with no round label.
• Automation is unfinished. Venture Capital Tracker's reading of Lightspeed's investment memo describes automation as still being built out, with expert chemists doing much of the early work.
• Customer data. The company emphasizes intellectual property protection, but the coverage does not clearly define whether customer data may be used to train its AI models.
• Execution. The $215 million has to pay for physical lab capacity and software systems at the same time. The coverage describes this as an execution challenge.
• Weakest point. Demand for AI-driven drug discovery services is crowded. No customer, price or throughput data has been published, so the case rests on the plan and the funding.

Taken together, the open questions cluster in three places: the company's own account of its automation, the source of its valuation, and its commercial traction. Each one could be answered by a filing, a named customer or a published price list, and none of those appears in the coverage reviewed. Readers should treat the round as confirmed by several outlets and the valuation as company-sourced until a primary document says otherwise.